Cellebrite DI Ltd. (CLBT)

Market Closed

1 Sep, 20:00

NASDAQ (NGS)

11. 85

-0.15

-1.25%

After Hours

12. 22

+0.37 +3.1224%

2.99B Market Cap

- P/E Ratio

- Div Yield

1.77M Volume

- Eps

$ 12

Previous Close

Investors:

+31

Analysts:

Add Transaction

Day Range

11.81 11.98

Year Range

9.58 19.98

Want to track CLBT and more in your Portfolio? 🎯

Get Started For Free

Cellebrite DI Ltd. (CLBT) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 weeks ago

Cellebrite DI Q2 Earnings Call Highlights

Cellebrite DI NASDAQ: CLBT reported second-quarter results that fell short of its expectations for annual recurring revenue, citing delayed large transactions, slower-than-anticipated pricing and expansion gains from customer migrations, and added procurement requirements for cloud and artificial intelligence offerings. The company lowered its full-year ARR and revenue outlook while raising its adjusted EBITDA target.

Marketbeat | 2 weeks ago

Cellebrite DI Ltd. (CLBT) Q2 Earnings and Revenues Miss Estimates

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12 per share.

Zacks | 2 weeks ago

Cellebrite DI Eyes AI, Cloud and FedRAMP as Digital Investigations Demand Grows

Cellebrite DI NASDAQ: CLBT executives said the company is seeing broader customer adoption of its digital investigations platform, with artificial intelligence, cloud migration and U.S. federal authorization expected to shape its next phase of growth.

Marketbeat | 3 months ago

Cellebrite DI Sees Federal Rebound as AI, Defense Tools Fuel New Growth

Cellebrite DI NASDAQ: CLBT executives said the digital investigations company is seeing renewed momentum in government demand, international markets and new product categories, including artificial intelligence and defense-focused capabilities, during a JPMorgan cybersecurity and DevOps event hosted by analyst Brian Essex.

Marketbeat | 3 months ago

Cellebrite DI Ltd. (CLBT) Presents at J.P.

Seekingalpha | 3 months ago

Cellebrite: Positive Q1 Results, But There Is Room For Margin Improvements

Cellebrite delivered strong Q1 2026 results, with 19% revenue growth and notable subscription and ARR gains, beating analyst expectations. CLBT expanded its portfolio with the SCG Canada acquisition and launched AI-powered solutions, positioning itself for long-term growth and broader market reach. Despite robust top-line growth, gross, operating, and net margins declined; margin expansion remains a key area to monitor.

Seekingalpha | 3 months ago

Cellebrite DI Q1 Earnings Call Highlights

Cellebrite DI NASDAQ: CLBT reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives highlighted a wave of new product launches centered on artificial intelligence, cloud-based case management and mobile device access.

Marketbeat | 3 months ago

Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Top Estimates

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share.

Zacks | 3 months ago

Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat

Cellebrite DI operates in a niche with strong regulatory moats, high switching costs, and robust customer entrenchment. CLBT's financials are solid: subscription revenue up 21%, ARR at $481M, Rule of 40 above 55, and FCF margin at 34%. AI integration enhances CLBT's value proposition, accelerating evidence discovery and reinforcing its competitive positioning and growth prospects.

Seekingalpha | 4 months ago

Cellebrite DI Ltd. (CLBT) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Seekingalpha | 6 months ago

Cellebrite DI Ltd. (CLBT) Q4 2025 Earnings Call Transcript

Seekingalpha | 6 months ago

Blog Affiliate Program About Terms Privacy Help Contact Us